Nanyang Biologics and Precisya Global Form Strategic Alliance to Leverage AI in Validating Natural Compounds for Genetic Risk Mitigation

Nanyang Biologics (NYB) and Precisya Global Inc. (PGI) have formed an joint initiative to combine AI-powered compound discovery with advanced genetic risk profiling, bringing a new dimension to precision health through nature-derived interventions.

‍

Bridging Genomics & Nature Through AI

‍

The collaboration integrates genomic analysis with natural compound research, leveraging AI-driven matching and comprehensive validation processes to expedite the development of plant-based treatments for genetic conditions. The initiative enables the development of precisely targeted natural interventions, delivering enhanced therapeutic efficacy, reduced adverse effects, and cost-effective solutions for individuals with genetic predispositions.

‍

At the heart of this initiative, Nanyang Biologics’ DTIGN (Drug-Target Interaction Graph Neural Network) platform will screen its extensive library of plant-based compounds, delivering 27% greater accuracy in predicting drug-target interactions compared to leading benchmarks. Precisya Global Inc will augment this process by supplying secure access to anonymized patient genomic data and advanced bioinformatic analysis, enabling the correlation of compound responses with specific genetic variants.

‍

What’s Next?

‍

In the coming months, NYB and PGI will begin preclinical validation, leveraging biobank data and molecular docking simulations, followed by in vitro and in vivo testing. The partnership also paves the way for co-branded, gene-informed ingredient formulations for health-conscious consumers and medical professionals alike.

‍

For patients, especially those with genetically predisposed chronic diseases,this collaboration could mean earlier interventions, improved outcomes, and personalized treatments derived from nature with scientific backing. For healthcare and R&D ecosystems, it marks a paradigm shift: a move from generalized treatments to precision-first design powered by AI and genomics.

‍

About Precisya Global Inc

Precisya Global Inc. (PGI) is a biotechnology company headquartered in the United States, offering cutting-edge genomic risk prediction tools. PGI helps patients, researchers, and healthcare providers better understand individual genetic risk factors, with applications in early detection, precision prevention, and personalized care pathways.

‍

About Nanyang Biologics

Nanyang Biologics (NYB) is a Singapore-based biotech innovator specializing in AI-driven discovery of plant-based bioactives. With its proprietary DTIGN platform, NYB accelerates natural compound validation for nutraceutical, pharmaceutical, and functional health applications—bridging the gap between traditional medicine and modern science.